{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:09:30Z","timestamp":1760234970386,"version":"build-2065373602"},"reference-count":50,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>This study analyses the influence of the course of the disease of idiopathic cervical dystonia (CD) before botulinum toxin (BoNT) therapy on long-term outcomes. 74 CD-patients who were treated on a regular basis in the botulinum toxin outpatient department of the University of D\u00fcsseldorf and had received at least 3 injections were consecutively recruited after written informed consent. Patients were asked to rate the amount of change of CD in relation to the severity of CD at begin of BoNT therapy (IMPQ). Then they had to draw the course of disease of CD from onset of symptoms until initiation of BoNT therapy (CoDB-graph) on a sheet of paper into a square of 10 \u00d7 10 cm2 size. Remaining severity of CD was estimated by the treating physician using the TSUI-score. Demographical and treatment related data were extracted from the charts of the patients. Depending on the curvature four different types of CoDB-graphs could be distinguished. Time to BoNT therapy, increase of dose and improvement during BoNT treatment were significantly (p &lt; 0.05) different when patients were split up according to CoDB-graph types. The lower the age at onset of symptoms, the shorter was the time to therapy (p &lt; 0.02). Initial dose (p &lt; 0.04) and actual dose (p &lt; 0.009) were negatively correlated with the age of the patients at recruitment. The course of disease of CD before BoNT therapy has influence on long-term outcome. This has implications on patient management and information on the efficacy of BoNT treatment.<\/jats:p>","DOI":"10.3390\/toxins13070493","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T21:18:52Z","timestamp":1626643132000},"page":"493","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-7684","authenticated-orcid":false,"given":"Harald","family":"Hefter","sequence":"first","affiliation":[{"name":"Department of Neurology, Moorenstrasse 5, D-40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Schomaecker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Moorenstrasse 5, D-40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Schomaecker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Moorenstrasse 5, D-40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Moorenstrasse 5, D-40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3593-1852","authenticated-orcid":false,"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Moorenstrasse 5, D-40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Epidemiological Study of Dystonia in Europe Collaborative Group (1999). Sex-related influences on the frequency and age of onset of primary dystonia. Neurology, 53, 1871\u20131873.","DOI":"10.1212\/WNL.53.8.1871"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/mds.25244","article-title":"The prevalence of primary dystonia: A systematic review and meta-ananlysis","volume":"27","author":"Steeves","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fneur.2017.00035","article-title":"Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin","volume":"8","author":"Contarino","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jns.2016.11.053","article-title":"Meige\u2019s syndrome: History, epidemiology, clinical features, pathogenesis and treatment","volume":"372","author":"Pandey","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group (2000). A prevalence study of primary dystonia in eight European countries. J. Neurol., 247, 787\u2013792.","DOI":"10.1007\/s004150070094"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mds.870030302","article-title":"Epidemiology of focal and generalized dystonia in Rochester, Minnesota","volume":"3","author":"Nutt","year":"1988","journal-title":"Mov. Disord."},{"key":"ref_7","first-page":"CD003633","article-title":"Botulinum toin type A therapy for cervical dystonia","volume":"11","author":"Rodrigues","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: Clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Mov. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: A consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00702-020-02266-z","article-title":"Botulinum toxin therapy of dystonia","volume":"128","author":"Dressler","year":"2021","journal-title":"J. Neural Transm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"German Dystonia Study Group. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency","volume":"246","author":"Kessler","year":"1999","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X","article-title":"Patients\u2019perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A","volume":"15","author":"Brashear","year":"2000","journal-title":"Mov. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","article-title":"Long-term follow-up of cervical dystonia patients treated with botulinum toxin A","volume":"19","author":"Haussermann","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-1331.2004.01053.x","article-title":"The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment","volume":"12","author":"Skogseid","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/toxins5040776","article-title":"Continuation of long-term care for cervical dystonia at an academic movement disorder clinic","volume":"5","author":"Gill","year":"2013","journal-title":"Toxins"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.toxicon.2017.09.004","article-title":"Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?","volume":"147","author":"Jinnah","year":"2018","journal-title":"Toxicon"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1017\/S0012162206000697","article-title":"Why do children with cerebral palsy discontinue therapy with botulinum toxin A?","volume":"48","author":"Kirschner","year":"2006","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Samadzadeh, S., Brauns, R., and Hefter, H. (2021). The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia. Toxins, 13.","DOI":"10.3390\/toxins13010022"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy","volume":"19 (Supp. Sl)","author":"Dressler","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.parkreldis.2009.06.004","article-title":"Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients","volume":"16","author":"Maia","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"588395","DOI":"10.3389\/fneur.2020.588395","article-title":"Disease progression of idiopathic cervical dystonia in spite of improvement after botulinum toxin therapy","volume":"11","author":"Hefter","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bellows, S., and Jankovic, J. (2019). Immunogenicity associated with botulinum toxin treatment. Toxins, 11.","DOI":"10.3390\/toxins11090491"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00415-016-8136-x","article-title":"Botulinum toxin treatment failures in cervical dystonia: Causes, management, and outcomes","volume":"263","author":"Jinnah","year":"2016","journal-title":"J. Neurol."},{"key":"ref_29","first-page":"37","article-title":"Which patients discontinue treatment with botulinum toxin in cervical dystonia?","volume":"10","author":"Erbguth","year":"1995","journal-title":"Mov. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.baga.2012.03.003","article-title":"CT-guided intramuscular botulinum toxin A injections into the deep anterior neck muscles in patients with pure antecaput or antecollis","volume":"2","author":"Hefter","year":"2012","journal-title":"Basal Ganglia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mdc3.12322","article-title":"High Botulinum Toxin-Neutralizing Antibody Prevalence Under Long-Term Cervical Dystonia Treatment","volume":"3","author":"Hefter","year":"2016","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Samadzadeh, S., \u00dcrer, B., Brauns, R., Rosenthal, D., Lee, J.-I., Albrecht, P., and Hefter, H. (2020). Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature. Toxins, 12.","DOI":"10.3390\/toxins12080499"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bellows, S., and Jankovic, J. (2020). Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491. Toxins, 12.","DOI":"10.3390\/toxins12020072"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: A cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archneur.1990.00530050070014","article-title":"Natural History of adult-onset idiopathic torticollis","volume":"47","author":"Jahanshahi","year":"1990","journal-title":"Arch. Neurol."},{"key":"ref_38","first-page":"210","article-title":"Cervical dystonia (spasmodic torticollis). Some aspects of the natural history","volume":"95","year":"1995","journal-title":"Acta Neurol. Bel."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/mds.870100204","article-title":"Spread of symptoms in idiopathic torsion dystonia","volume":"10","author":"Greene","year":"1995","journal-title":"Mov. Disord."},{"key":"ref_40","unstructured":"Moore, P., and Naumann, M. (2003). Cervical and axial dystonia. Handbook of Botulinum Toxin Treatment, Blackwell Science. [2nd ed.]."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/nmt-2018-0047","article-title":"Update on current and emerging therapies for dystonia","volume":"9","author":"Lizzarga","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00415-011-5961-9","article-title":"Factors predicting protracted improvement after pallidal DBS for primary dystonia: The role of age and disease duration","volume":"258","author":"Isaias","year":"2011","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(14)70143-7","article-title":"Pallidal neurostimulation in patients with mediation-refractory cervical dystonia: A randomized, sham-controlled trial","volume":"13","author":"Volkmann","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00415-020-10128-7","article-title":"The impact of the initial severity on later outcome: Retrospective analysis of a large cohort of botulinum toxin na\u00efve patients with idiopathic cervical dystonia","volume":"268","author":"Hefter","year":"2021","journal-title":"J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1212\/WNL.38.4.530","article-title":"The clinical course of spasmodic torticollis","volume":"38","author":"Lowenstein","year":"1988","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(71)92318-X","article-title":"Natural history of spasmodic torticollis, and effect of surgery","volume":"17","author":"Meares","year":"1971","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2019.02.020","article-title":"Remission in dystonia\u2014Systematic review of the literature and meta-analysis","volume":"66","author":"Mainka","year":"2019","journal-title":"Parkinsonosm Relat. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e001853","DOI":"10.1136\/bmjopen-2012-001853","article-title":"An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)","volume":"3","author":"Hefter","year":"2013","journal-title":"BMJ Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.parkreldis.2018.07.019","article-title":"Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study","volume":"57","author":"Moll","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00115-012-3708-1","article-title":"Botulinum-Toxin-Therapie bei Torticollis spasmodicus","volume":"84","author":"Leplow","year":"2013","journal-title":"Der Nervenarzt"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/7\/493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:30:47Z","timestamp":1760164247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/7\/493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["toxins13070493"],"URL":"https:\/\/doi.org\/10.3390\/toxins13070493","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2021,7,16]]}}}